Published in Neurogastroenterol Motil on May 15, 2008
Rat β₃-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.88
Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.84
The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease. Front Immunol (2015) 0.79
An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. J Cell Mol Med (2014) 0.79
Alleviation of antioxidant defense system by ozonized olive oil in DNBS-induced colitis in rats. Mediators Inflamm (2014) 0.78
Anti-inflammatory effects of beta3-adrenoceptors: the burgeoning field of neurogastroimmunology. Neurogastroenterol Motil (2008) 0.75
Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut (2008) 3.52
Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology (1996) 3.22
New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J Med Chem (1997) 2.66
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther (2009) 2.41
Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med (2000) 2.40
Gastro-oesophageal reflux and interstitial lung disease. Dig Liver Dis (2006) 1.85
Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther (2009) 1.83
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci (2006) 1.80
Differential expression of two vesicular monoamine transporters. J Neurosci (1995) 1.75
JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. Gut (2008) 1.59
Editorial: hyponatremia - a possible but forgotten consequence of bowel preparation for colonoscopy. Aliment Pharmacol Ther (2014) 1.45
Editorial: adequate management may reduce the colorectal cancer risk associated with constipation. Aliment Pharmacol Ther (2014) 1.42
Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil (2007) 1.35
Presence of a non-adrenergic inhibitory system in the human colon. Gut (1968) 1.35
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol (1996) 1.32
New insights into human enteric neuropathies. Neurogastroenterol Motil (2004) 1.31
Review article: the pharmacological treatment of acute colonic pseudo-obstruction. Aliment Pharmacol Ther (2001) 1.24
Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther (2008) 1.24
Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci U S A (1999) 1.22
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology (1999) 1.16
Beta 3-adrenoceptors and intestinal motility. Fundam Clin Pharmacol (1995) 1.14
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol (2001) 1.12
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10
Esophageal and gastric nitric oxide synthesizing innervation in primary achalasia. Am J Gastroenterol (1999) 1.09
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res (2000) 1.09
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol (1997) 1.07
Predominant symptoms identify different subgroups in functional dyspepsia. Am J Gastroenterol (1999) 1.07
Clinical findings and anti-neuronal antibodies in coeliac disease with neurological disorders. Scand J Gastroenterol (2002) 1.02
Role of nitric oxide- and vasoactive intestinal polypeptide-containing neurones in human gastric fundus strip relaxations. Br J Pharmacol (2000) 1.02
Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol (2014) 1.02
Primary enteric neuropathies underlying gastrointestinal motor dysfunction. Scand J Gastroenterol (2000) 1.01
Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol (1999) 1.00
Proceedings: Prostaglandins in human colonic carcinoma. Gut (1975) 1.00
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat (2001) 0.99
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol (2002) 0.99
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol (2001) 0.98
Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. Eur J Gastroenterol Hepatol (2000) 0.97
Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer (1993) 0.97
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol (2005) 0.97
Inhibition of rat colonic motility and cardiovascular effects of new gut-specific beta-adrenergic phenylethanolaminotetralines. Life Sci (1989) 0.96
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer (2005) 0.96
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer (2006) 0.96
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol (1999) 0.96
Periodontal tissue disposition of azithromycin. J Periodontol (1997) 0.95
Somatostatin 2A receptor is expressed by enteric neurons, and by interstitial cells of Cajal and enterochromaffin-like cells of the gastrointestinal tract. J Comp Neurol (1997) 0.95
Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut (2005) 0.95
Hematologic toxicity of immunosuppressive treatment. Transplant Proc (2004) 0.94
Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil (2013) 0.94
The actions of atropine, tropenziline and N-butyl hyoscine bromide on the isolated distal colon of the guinea-pig: a comparison of their activities and mechanisms of action. J Pharm Pharmacol (1969) 0.94
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol (2001) 0.94
Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. Br J Pharmacol (2010) 0.94
Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut (2009) 0.94
Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis (2002) 0.94
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer (2005) 0.94
The effect of lipoproteins on endothelial nitric oxide synthase is modulated by lipoperoxides. Eur J Clin Invest (2003) 0.94
Experiments on the mechanism of action of caerulein at the level of the guinea-pig ileum and colon. Agents Actions (1970) 0.93
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol (2001) 0.93
Might adriamycinol contribute to adriamycin-induced cardiotoxicity? Pharmacol Res Commun (1985) 0.93
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer (2011) 0.92
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer (2008) 0.92
Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Dig Dis Sci (1999) 0.92
Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet (1999) 0.92
In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. Mol Hum Reprod (2001) 0.92
Antagonism of atropine towards endogenous and exogenous acetylcholine before and after sympathetic system blockade in the isolated distal guinea-pig colon. Eur J Pharmacol (1968) 0.92
The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. Br J Pharmacol (2004) 0.91
Histamine H(3) receptors mediate inhibition of noradrenaline release from intestinal sympathetic nerves. Br J Pharmacol (2000) 0.90
Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil (2012) 0.90
Pharmacological studies on the mechanisms underlying the inhibitory and excitatory effects of clonidine on gastric acid secretion. Eur J Pharmacol (1982) 0.90
'Blood On The Tracks' from corpora lutea to endometriomas. BJOG (2009) 0.90
Some observations on the intrinsic nervous mechanism in Hirschsprung's disease. Gut (1973) 0.89
Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. Transplant Proc (2010) 0.89
Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil (2012) 0.89
Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase. Anticancer Res (1987) 0.89
Upper gastrointestinal bleeding due to duodenal metastasis from primary lung carcinoma. Dig Liver Dis (2002) 0.89
In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a beta3-adrenoceptor-mediated effect. Eur J Pharmacol (1998) 0.89
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol (2002) 0.89
Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.89
Detection of substance P immunoreactivity in human peripheral leukocytes. J Neuroimmunol (1998) 0.89
Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the ALADIN locus. Dig Liver Dis (2005) 0.89
Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut (2006) 0.89
Effects of imidazoline derivatives on cholinergic motility in guinea-pig ileum: involvement of presynaptic alpha2-adrenoceptors or imidazoline receptors? Naunyn Schmiedebergs Arch Pharmacol (1998) 0.89
Common variable immunodeficiency in vitiligo. G Ital Dermatol Venereol (2010) 0.88
Immunohistochemical demonstration of the small GTPase RhoA on epoxy-resin embedded sections. Micron (2004) 0.88